IRD Opus Genetics, Inc. Insider Trading

FFB Retinal Degeneration Fund sold 1,700,000 shares (1.70M) of IRD at $4.35; stock now at $4.44, -23.6% from 52-week high.

Foundation Fighting Blindness Retinal Degeneration Fund, a director, divested 1,700,000 shares (1.70M shares) in a $7,395,000.00 sale at $4.35 on 2026-05-18, reducing holdings from 5,492,171 to 3,792,171 shares (-31.0% vs pre-transaction holdings). The sale occurs with the stock trading -23.6% from its 52-week high and having declined -19.9% over the prior 30 days, though it has gained +24.4% over 90 days. IRD is unprofitable, posting a net income of $-65,535,000.00 while generating only $2,157,000.00 in latest quarterly revenue, though annual revenue growth stands at +29.2%. The prior sale by this insider at this ticker (2025-12-09) delivered a 90-day return of +121.9%, a poorly-timed outcome relative to the insider's stated transaction pattern. The scale of this reduction—shedding nearly one-third of the existing position—paired with the company's significant losses and the stock's recent weakness merit investor attention to the timing and any accompanying disclosures around director positioning.

Director Cam Gallagher purchases 164,000 shares at $1.97–$1.98 for $323.7K, raising stake 9.3% amid -42.3% revenue decline and $-17.5M annual loss.

Director Cam Gallagher executed two separate purchases totaling 164,000 shares for $323,693.40 on 2025-12-29 at prices of $1.98 and $1.97, increasing his holdings from 1,760,430 to 1,924,430 shares (+9.3%). The timing occurs within a deteriorating operational backdrop: the company reported annual revenue decline of -42.3% year-over-year, a net loss of $-17,454,000.00 for the full fiscal year, and quarterly revenue of $3,079,000.00. The current stock price of $2.01 sits -19.6% below the 52-week high of $2.50, placing the transaction within 1.5% of current market levels. Investors should note the magnitude of the director's open-market commitment—164.0K shares represents meaningful capital allocation—alongside the concurrent negative fundamentals and margin erosion, which warrant assessment of what visibility or strategic rationale this purchase reflects given Opus Genetics' unprofitable status and steep revenue contraction.

Director (Foundation Fighting Blindness) sold 4,000,000 shares at $2.15; exits 42.1% of stake from Opus Genetics unprofitable biotech.

Foundation Fighting Blindness Retinal Degeneration Fund (Director) divested 4,000,000 shares at $2.15 on 2025-12-09, reducing holdings from 9,492,171 shares to 5,492,171 shares—a 42.1% reduction in stake. This occurs in the context of deteriorating fundamentals: the company posted net income of $-17,454,000.00 for its most recent full fiscal year, quarterly revenue of $3,079,000.00, and year-over-year annual revenue decline of -42.3%. The sale price of $2.15 sits near the 52-week high of $2.50, and recent momentum (+76.8% over 90 days, +23.9% over 30 days) suggests the insider captured strength before the transaction. The material scale of the position reduction—eliminating nearly half the director's holdings—signals a structural shift in exposure to a loss-making enterprise facing significant revenue contraction.

CEO George Magrath buys 100,000 shares (100.0K) of Opus Genetics at $0.98 on 2024-12-26, raising stake to 599,150 shares.

George Magrath, Chief Executive Officer of Opus Genetics, purchased 100,000 shares at $0.98 on 2024-12-26, a 20.0% increase in his holdings. The stock currently trades at $1.12, placing the transaction price 17% below the 52-week high of $1.35. This is his third open-market purchase at IRD in roughly six weeks, following buys on 2024-11-15 and 2024-11-18. However, the company's fundamentals present significant headwinds: annual revenue contracted 52.2% year-over-year to $3.9M in the latest quarter, the company posted net income of $-7.5M on an unprofitable basis, and the market cap is $35.4M. Magrath's cross-ticker track record shows 4 prior buys with an average 90-day return of -22.6% and a 0.00% win rate, though same-ticker outcomes at IRD remain partially unmeasurable. The accumulation pattern warrants examination given the deteriorating revenue trajectory and persistent losses.

President Benjamin R Yerxa buys 10,000 shares of Opus Genetics at $0.98; company faces steep -52.2% annual revenue decline and $7.5M loss.

Benjamin R Yerxa, as President of Opus Genetics, purchased 10,000 shares at $0.98 on 2024-11-21, increasing his holdings from 332,800 to 342,800 shares (+3.0%). The company is unprofitable, reporting a net income of $-7,526,000.00 and annual revenue growth of -52.2%, while trading on a recent listing (23 trading days). The purchase occurred at $0.98 against a current price of $1.10, a modest premium post-transaction. The context—significant revenue contraction and substantial operating losses—suggests operational headwinds that warrant scrutiny of the company's path to profitability, even as the President maintains equity exposure.

CEO George Magrath purchased 100,000 shares (100.0K shares) for $101,157.83 across 2 transactions at Opus Genetics (IRD), raising stake 25.4%.

George Magrath, CEO of Opus Genetics, executed 2 separate purchases totaling 100,000 shares for $101,157.83 on November 15 and November 18, 2024, increasing his holdings from 392,950 to 492,950 shares (+25.4%). The transactions occurred at an average price of $1.01, above the current market price of $0.88 as of November 19—a premium of roughly 15% to today's price. This substantial share acquisition by the Chief Executive Officer is notable given the company's material operational stress: revenue declined 52.2% year-over-year, the company reported a net loss of $7,526,000.00 in its latest quarter, and annual net income was negative. The timing and magnitude of this insider purchase, combined with the company's recent IPO status (19 trading days) and ongoing unprofitability, warrant careful attention to understand the CEO's view of valuation and company trajectory.